Safety, Tolerability, Pharmacokinetics of ELX-02 in Healthy Adult Volunteers
Phase 1a, Randomized, Double-blinded, Placebo-controlled, Single-dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ELX-02 in Healthy Adult Volunteers
Sponsor: Eloxx Pharmaceuticals, Inc.
Terminated
Transferred study to Antwerp, Belgium
Other terminated trials from Eloxx Pharmaceuticals, Inc.
More terminations from Eloxx Pharmaceuticals, Inc.
This PHASE1 trial investigates Genetic Diseases and Nonsense Mutations and is currently terminated or withdrawn. Eloxx Pharmaceuticals, Inc. leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Nov 2019 — Jan 2021 [monthly]
Terminated PHASE1
-
Jun 2018 — Nov 2019 [monthly]
Terminated PHASE1
▶ Show 2 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Terminated PHASE1
Status: Not Yet Recruiting → Terminated
-
Jan 2017 — Sep 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eloxx Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.